Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2003-11-24
2008-05-27
Pak, Michael (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S002600
Reexamination Certificate
active
07378496
ABSTRACT:
The present invention is based on the discovery and cloning of the human small conductance calcium activated potassium channel type 3 (hKCa3/KCNN3) gene, which is expressed in neuronal cells, skeletal muscle, heart, and lymphocytes. Alterations in the hKCa3/KCNN3 gene or its protein product may enhance susceptibility to schizophrenia and/or bipolar disorder. hKCa3/KCNN3 may be involved in neuropsychiatric, neurological, neuromuscular, and immunological disorders. Substantially purified hKCa3/KCNN3 polypeptides and polynucleotides are provided. Antibodies which bind to hKCa3/KCNN3 polypeptides are also disclosed. A method for identifying a compound which affects hKCa3/KCNN3 polynucleotide or polypeptide is provided. A method for diagnosis and determining the prognosis and treatment regimen of a subject having or at risk of having a hKCa3/KCNN3-associated disorder is also provided. A method of treating a subject having or at risk of having an hKCa3/KCNN3-associated disorder by administering a therapeutically effective amount of a polynucleotide encoding SEQ ID NO:2 is also provided. A formulation for administration of hKCa3/KCNN3 to a patient of a therapeutically effective amount of hKCa3/KCNN3 polypeptide is provided. Kits useful for detecting the presence of hKCa3/KCNN3 polypeptide or polynucleotide in a sample from a subject having a hKCa3/KCNN3-associated disorder are provided. Transgenic nonhuman animals having a transgene encoding hKCa3/KCNN3 are also described.
REFERENCES:
patent: 5637470 (1997-06-01), Kaczorowski et al.
patent: 5776734 (1998-07-01), Kaczorowski et al.
patent: WO 98/11139 (1998-03-01), None
Bowie et al. (1989) Science 247: 1306-1310.
Imbert et al., Cloning of the gene for the spinocerebellar,Nature Genetics,vol. 14, pp. 258-291, Nov. 1996.
Imbert et al., “Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats”, Nature Genetics, vol. 14, pp. 285-291, Nov. 1996.
Stratagene catalog, p. 39, 1988.
Imbert et al., “Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats”,Nature Genetics,(1996), vol. 14, pp. 285-291.
Imbert et al., “Cloning of the Gene for Spinocerebellar Ataxia 2 Reveals a Locus with High Sensitivity to Expanded CAG/Glutamine Repeats,” Nature Genetics, vol. 14, No. 3, pp. 285-291, Nov. 1996.
M. Kohler, “Small-Conductance, Calcium-Activated Potassium Channels from Mammalian Brain,” Science, vol. 273, pp. 1625-1764, Sep. 1996.
William J. Joiner, “hSK4, A Member of a Novel Subfamily of Calcium-Activated Potassium Channels,” Neurobiology, vol. 94, pp. 11013-11018, Sep. 1997.
Takahiro M. Ishii, “A Human Intermediate Conductance Calcium-Activated Potassium Channel,” Neurobiology, vol. 94, pp. 11651-11656, Oct. 1997.
Gilliam P. Bates, “Transgenic Mouse Models of Neurodegenerative disease Cause by CAG/Polyglutamine Expansions,” Molecular Medicine Today, Nov. 1997.
P.S. Reddy et al., “The Complex Pathology of Trinucleotide Repeats” Current Opinion Cell Biology, vol. 9, No. 3, pp. 364-372, Jun. 1997.
Georges Imbert, Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats, Nov. 1996, Nature Genetics vol. 14 No. 3. , pp. 285-291.
M. Kohler, Small-Conductance, Calcium-Activated Potassium Channels from Mammalian Brain, Sep. 1996, Science, vol. 273 pp. 1625-1764.
William J. Joiner, hSK4, a member of a novel subfamily of calcium-activated potassium channels, Sep. 1997, Neurobiology, vol. 94 pp. 11013-11018.
Takahiro M. Ishii, A human intermediate conductance calcium-activated potassium channel, Oct. 1997, Neurobiology, vol. 94 pp. 11651-11656.
Gillian P. Bates, Tansgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions, Nov. 1997, Molecular Medicine Today.
P Sanjeeva Reddy, The complex pathology of trinucleotide repeats, Nucleus and gene expression, pp. 364-372.
T Bowen, Further support for an association between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia, 1998, Molecular Psychiatry.
Kohler et al., Small Conductance, Calcium-Activated Potassium Channels from Mammalian Brain. Science. Sep. 20, 1996, vol. 273, pp. 1709-1714, expecially figures 1A and 1C on p. 1710.
Chandy K. George
Fantino Emmanuelle
Gargus J. Jay
Gutman George
Kalman Katarin
DLA Piper (US) LLP
Pak Michael
The Regents of the University of California
LandOfFree
hKCa3/KCNN3 small conductance calcium activated potassium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with hKCa3/KCNN3 small conductance calcium activated potassium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and hKCa3/KCNN3 small conductance calcium activated potassium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3984742